March 3, 2021 — Medtronic announced new results from the landmark REVERSE trial, evaluating outcomes of cardiac resynchronization therapy (CRT) for patients with mild heart failure (HF).

March 3, 2021 — Impulse Dynamics recently announced that DEKRA Certification B.V., a global regulatory organization, approved labeling for the Optimizer Smart device for conditional full-body magnetic resonance imaging (MRI) scans utilizing 1.5 Tesla scanners in the European Union (EU).

March 3, 2021 — AliveCor recently announced a new collaboration with AstraZeneca to research new disease management solutions in cardiovascular, renal and metabolism (CVRM) therapeutic areas. The collaboration will translate AliveCor’s potassium detection technology and science, which enables potassium measurement outside of blood draws, into real-world disease management applications and solutions.

March 3, 2021 — Farapulse Inc. announced the first patients were treated in the ADVENT Trial, a U.S. Food and Drug Administration (FDA) investigational device exemption (IDE) pivotal trial to evaluate the safety and effectiveness of its Pulsed Field Ablation (PFA) system for the treatment of paroxysmal atrial fibrillation (AF). 

March 2, 2021 — Penn State Health Milton S. Hershey Medical Center became the second hospital in the nation to implant a newly-designed EvaHeart2 Left Ventricular Assist System (LVAS) in a patient with severe heart failure.

March 1, 2021 — Medtronic is recalling the HeartWare Ventricular Assist Device (HVAD) Pump Implant Kit because the left ventricular assist device (LVAD) device may fail to initially start, restart, or have a delay in restarting after the pump was stopped.

The two biggest cardiac device technology stories in February included the Boston Scientific recall of its S-ICD system, and the FDA clearance of the Shockwave intravascular lithotripsy system to break up calcified lesions in the coronary arteries.

March 1, 2021 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC) magazine website from the month of February 2021. This is based on the website’s 676,038 pageviews for the month.

1. The Long-term Cardiovascular Impact of COVID-19

2. Addressing Atrial Fibrillation in the World of COVID-19

March 1, 2021 — The U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the third vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The EUA issued Feb . 27, allows the Janssen Biotech COVID-19 Vaccine to be distributed in the U.S for use in individuals 18 years of age and older. 

February 25, 2021 — The first COVID-19 patient in the world was supported by the new Abiomed Breethe OXY-1 System, an advanced, compact, cardiopulmonary bypass system that pumps, oxygenates and removes carbon dioxide from the blood for patients whose lungs can no longer provide sufficient oxygenated blood.

Astronaut Jessica Meir “feeds” a set of the University of Washington’s engineered heart tissues (inside the green-topped case at center) riding aboard the International Space Station as part of a test of micro-gravity on heart health. Image courtesy of NASA. 

The University of Washington (UW) in Seattle has developed engineered heart tissue that beats. Though minuscule, the rice-grain sized tissues hold enormous promise for understanding one of the body’s most essential organ. Heart disease is the world’s leading cause of death. The new beating hearts, a sort of heart in a petri dish or organ in a dish, will allow researches to better understand cardiac function under various conditions or test the cardiac impact of new drugs.  
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now